Co-operation between follicular ornithine decarboxylase and v-Ha-ras induces spontaneous papillomas and malignant conversion in transgenic skin.
Ornithine decarboxylase (ODC) is aberrantly regulated in tumor cells and results in high basal levels of ODC and polyamines in many epithelial tumors. To determine if elevated ODC/polyamine levels can co-operate with a mutant Ha-ras gene in mouse skin tumorigenesis, double transgenic mice were generated by breeding K6/ODC transgenic mice with TG.AC v-Ha-ras transgenic mice. A K6 keratin promoter drives the ODC transgene in K6/ ODC transgenic mice, which results in elevated ODC/ polyamine levels directed to the outer root sheath cells of hair follicles. TG.AC transgenic mice carry a v-Ha-ras transgene while still retaining two normal c-Ha-ras alleles. Transgenic mice that possess only the K6/ODC or the v-Ha-ras transgene did not develop tumors unless treated with either a carcinogen or a tumor promoter, respectively. However, a high percentage of double transgenic mice possessing both the K6/ODC and v-Ha-ras transgenes developed spontaneous tumors. All tumors were well-differentiated keratoacanthomas, some of which progressed to carcinomas within 2 months. The development and the maintenance of these ODC/ras tumors was ODC-dependent since alpha-difluoromethylornithine (DFMO), a specific ODC inhibitor, prevented the formation and caused the regression of these tumors. These findings indicate that ODC overexpression and an activated Ha-ras are sufficient to produce a high rate of malignant transformation in an animal model. The ODC/ras double transgenic mouse provides a simple in vivo model without the use of chemical carcinogens or tumor promoters in which to test downstream effectors that play a key role in mediating the development of epithelial tumors resulting from the cooperation between ODC and v-Ha-ras.
Smith
M K
MK
Lankenau Medical Research Center, Wynnewood, PA 19096, USA.
Trempus
C S
CS
Gilmour
S K
SK
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002273:Carcinogens; D000518:Eflornithine / Q000627:therapeutic use; D011905:Genes, ras / Q000502:physiology*; D007636:Keratoacanthoma / Q000139:chemically induced / Q000188:drug therapy / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D009955:Ornithine Decarboxylase / Q000235:genetics / Q000378:metabolism*; D010212:Papilloma / Q000139:chemically induced / Q000188:drug therapy / Q000235:genetics*; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D012871:Skin Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000235:genetics; D012878:Skin Neoplasms / Q000139:chemically induced / Q000188:drug therapy / Q000235:genetics*; D013755:Tetradecanoylphorbol Acetate
D000970:Antineoplastic Agents; D002273:Carcinogens; D018809:Proliferating Cell Nuclear Antigen; D015127:9,10-Dimethyl-1,2-benzanthracene; D009955:Ornithine Decarboxylase; D013755:Tetradecanoylphorbol Acetate; D000518:Eflornithine